Larimar Therapeutics Inc   (LRMR)
Other Ticker:  
Price: $6.4600 $0.06 0.937%
Day's High: $6.88 Week Perf: -8.37 %
Day's Low: $ 6.35 30 Day Perf: -24.27 %
Volume (M): 244 52 Wk High: $ 13.68
Volume (M$): $ 1,576 52 Wk Avg: $4.88
Open: $6.47 52 Wk Low: $2.18

 Market Capitalization (Millions $) 284
 Shares Outstanding (Millions) 44
 Employees 110
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) -47
 Capital Exp. (TTM) (Millions $) 0

Larimar Therapeutics Inc
Larimar Therapeutics Inc. is a clinical-stage biotechnology company that was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. The company is focused on developing novel treatments for complex rare diseases, with a particular focus on disorders that affect metabolism or the central nervous system.

Larimar Therapeutics is committed to addressing the significant unmet medical needs in rare diseases that currently have limited or no treatment options. To achieve this goal, the company employs a range of strategies, including gene therapy, protein replacement therapy, and small molecule therapeutics. Larimar's approach is to target specific genetic defects or mutations that underlie rare diseases and to develop treatments that address these underlying causes.

The company's flagship product candidate is CTI-1601, a recombinant fusion protein that is designed to replace the missing enzyme in patients with cystinosis, a rare metabolic disorder. CTI-1601 has received orphan drug designation from the FDA and European Medicines Agency, and the company is currently conducting a Phase I/II clinical trial to evaluate its safety and efficacy in cystinosis patients.

In addition to CTI-1601, Larimar Therapeutics is also developing a pipeline of other product candidates for rare diseases. These include small molecule therapies for Friedreich's ataxia and Niemann-Pick disease type C, as well as gene therapy for Pelizaeus-Merzbacher disease and GM1 gangliosidosis.

Larimar Therapeutics is a publicly traded company on the NASDAQ exchange under the ticker symbol "LRMR." The company has attracted significant attention from investors due to its innovative approach to treating rare diseases and its potential to transform the lives of patients with limited treatment options. The current market capitalization of the company is around $450 million.

   Company Address: Three Bala Plaza East Bala Cynwyd 19004 PA
   Company Phone Number: 511-9056   Stock Exchange / Ticker: NASDAQ LRMR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Exploring the Potential of Nomlabofusp in the Long-term Treatment of Friedreich's Ataxia: An Open Label Extension Study

Published Mon, Mar 11 2024 8:05 PM UTC

Friedreich's ataxia (FA) is a debilitating, progressive, and rare neurological disorder that primarily affects the nervous system and muscles. It is caused by a genetic mutation that leads to reduced levels of frataxin, a protein critical for mitochondrial function. Larimar Therapeutics, a clinical-stage biotechnology company, is at the forefront of developing a promising tr...

Financing Agreement

Larimar Therapeutics Raises $172.5 Million in Successful Public Offering, Driving Innovation in Rare Disease Treatment Sector

Published Fri, Feb 16 2024 9:20 PM UTC

BALA CYNWYD, Pa., Feb. 16, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a leading biotechnology company specializing in the development of treatments for rare diseases, has successfully completed its underwritten public offering of common stock. The offering, which included the full exercise of the underwriter's option to purchase additional shares, raised app...


Larimar Therapeutics Raises $150 Million in Underwritten Public Offering of Common Stock

Published Wed, Feb 14 2024 11:15 AM UTC

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
BALA CYNWYD, Pa., Feb. 14, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, has recently disclosed the pricing of its underwritten public offering of 17,162,472 shares of its c...

Financing Agreement

Larimar Therapeutics Aims to Secure Future with Proposed Underwritten Public Offering

Published Tue, Feb 13 2024 9:18 PM UTC

Larimar Therapeutics' Proposed Underwritten Public Offering and its Implications
Larimar Therapeutics, a clinical-stage biotechnology company specializing in developing treatments for complex rare diseases, recently made an important announcement regarding its future plans. The company has commenced an underwritten public offering, involving the sale of shares of its co...

Management Announcement

Larimar Therapeutics' Groundbreaking Study Shows Promise in Rare Friedreich's Ataxia Treatment

Published Mon, Feb 12 2024 12:00 PM UTC

Larimar Therapeutics' Promising Phase 2 Study Indicates Potential Breakthrough in Friedreich's Ataxia Treatment
BALA CYNWYD, Pa. - Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, has announced positive top-line data from its Phase 2 dose exploration study of nomlabofusp (CTI-1601) in patients with F...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com